STAGE-SPECIFIC DRUG THERAPIES AND TREATMENT STRATEGIES FOR HEPATOCELLULAR CARCINOMA
Main Article Content
Keywords
........
Abstract
Hepatocelluler cell cancer (HCC) is the top form of liver cancer & a key cause of death from cancer all over the world. What you can do to treat it rests much on how far it has gone, how the liver works, & how the sick one is doing. The Barcelona Clinic Liver Cancer (BCLC) list helps guide what to do in the clinic. Cures that can fix it, like cut out part of the liver, give a new liver, & small area burn are good for the start phase. For the mid phase, the go-to is TACE. For far-gone HCC, whole body drugs are key. Sorafenib was the first multi-use drug block to be okayed. It was top choice for a long time, though it has its limits due to not working after a bit & harm done. Since then, a lot more drugs like lenvatinib, regorafenib, cabozantinib, & ramucirumab have made more ways to treat. Also, drugs that block bad immune marks like nivolumab, pembrolizumab, & the mix of atezolizumab with bevacizumab have shown they help live longer for some. There are new study looks at mix of many drugs to block to fight the sickness in more ways & to do better overall. For the end stage HCC, the care aims to ease pain & help make life feel better. This text sums up the most recent ways to use drugs at each stage of HCC, shows the move from just one drug to many at once, & the hard tries still made to get the best out from treating it.
References
1. Li, Q., Ding, C., Cao, M., Yang, F., Yan, X., He, S., Cao, M., Zhang, S., Teng, Y., Tan, N., Wang, J., Xia, C. & Chen, W., 2024. Global epidemiology of liver cancer 2022: An emphasis on geographic disparities. Chinese Medical Journal, 137(19), pp.2334–2342.
2. Amin, N., Anwar, J., Sulaiman, A., Naumova, N. N. & Anwar, N., 2025. Hepatocellular Carcinoma: A Comprehensive Review. Diseases, 13(7), 207. doi:10.3390/diseases13070207
3. Wu, C.-Y., Lin, L.-Y., Lee, T.-Y., Hsu, Y.-C., Yeh, C.-C., Chen, C., Kang, Y.-N. & Huang, T.-W., 2024. Clinical guidelines for early hepatocellular carcinoma treatment options: a systematic review and bibliometric analysis. International Journal of Surgery, 110(11), pp.7234–7244. doi:10.1097/JS9.0000000000001950.
4. Zheng, S., Chan, S.W., Liu, F., Liu, J., Chow, P.K.H., Toh, H.C. & Hong, W., 2024. Hepatocellular carcinoma: current drug therapeutic status, advances and challenges. Cancers, 16(8), 1582.
5. Hatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S., 2023. Treatment Strategy for Intermediate Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers, 15(6), 1798. DOI: 10.3390/cancers15061798.
6. https://www.sciencedirect.com/science/article/abs/pii/S0305737210001313
7. Rose, M.G., Kennedy, E.B., Abou-Alfa, G.K., Finn, R.S., Gade, T., Kelley, R., Taddei, T., Gordan, J.D., 2024. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. Journal of Clinical Oncology, 42(8), pp. 1–14.
8. Zhou, Y., Zhang, Y., Wang, Z., Wang, J., Li, X., Xu, X., et al., 2025. Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation. Frontiers in Pharmacology, 14, 1581820
9. Chava, S., Ekmen, N., Ferraris, P., Aydin, Y., Moroz, K., Wu, T., Thung, S.N. & Dash, S., 2024. Mechanisms of Sorafenib Resistance in HCC Culture Relate to the Impaired Membrane Expression of Organic Cation Transporter 1 (OCT1). Journal of Hepatocellular Carcinoma, 11, pp. 839–855. doi:10.2147/JHC.S452152
10. Chen, S., Du, Y., Guan, X.-Y. & Yan, Q., 2023. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma. Frontiers in Oncology, 13, 1204513. doi:10.3389/fonc.2023.1204513
11. Suyama, K. & Iwase, H., 2018. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control, 25(1), 1073274818789361. doi:10.1177/1073274818789361
12. Grothey, A., Blay, J.-Y., Pavlakis, N., Yoshino, T. & Bruix, J., 2020. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews, 86, 101993. doi:10.1016/j.ctrv.2020.101993
13. Maroto, P., Porta, C., Capdevila, J., Apolo, A.B., Viteri, S., Rodriguez Antona, C., Martín, L. & Castellano, D., 2022. Cabozantinib for the treatment of solid tumours: a systematic review. Therapeutic Advances in Medical Oncology, 14, 17588359221107112. doi:10.1177/17588359221107112
14. Takebe, N., Beumer, J. H., Kummar, S., et al., 2019. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. British Journal of Clinical Pharmacology, 85(11), pp.2499–2511. doi:10.1111/bcp.14054
15. Jones, R.L., Ratain, M.J., O’Dwyer, P.J., Siu, L.L., Jassem, J., Medioni, J., DeJonge, M., Rudin, C., Sawyer, M., Khayat, D., Awada, A., de Vos Geelen, J.M.P.G.M., Evans, T.R.J., Obel, J., Brockstein, B., DeGreve, J., Baurain, J.-F., Maki, R., D’Adamo, D., Dickson, M., Undevia, S., Geary, D., Janisch, L., Bedard, P.L., Abdul Razak, A.R., Kristeleit, R., Vitfell Rasmussen, J., Walters, I., Kaye, S.B. & Schwartz, G., 2019. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 120, pp.132–139. doi:10.1016/j.ejca.2019.07.024
16. Chaudhari, M., Kumari, N., & Singh, S., 2025. Emerging Research and Future Directions on Doxorubicin: A Snapshot. Asian Pacific Journal of Cancer Prevention, 26(1), pp.5–14. doi:10.31557/APJCP.2025.26.1.5
17. Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S.A., Basiri, A. & Taheri, M., 2021. 5-Fluorouracil: A narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent. Frontiers in Oncology, 11, p.658636. doi:10.3389/fonc.2021.658636
18. Zhang, J., Zong, Y., Xu, G.-Z. & Xing, K., 2016. Erlotinib for advanced hepatocellular carcinoma: A systematic review of phase II/III clinical trials. Saudi Medical Journal, 37(11), pp.1184–1190. doi:10.15537/smj.2016.11.16267
19. Yamanaka, K., Petrulionis, M., Lin, S., Gao, C., Galli, U., Richter, S., Winkler, S., Houben, P., Schultze, D., Hatano, E. & Schemmer, P., 2013. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis. Cancer Medicine, 2(6), pp.862–871. doi:10.1002/cam4.150
20. Hijona, E., Banales, J.M., Hijona, L., Medina, J.F., Arenas, J., Herreros-Villanueva, M., Aldazabal, P. & Bujanda, L., 2012. Pravastatin inhibits cell proliferation and increases MAT1A expression in hepatocarcinoma cells and in vivo models. Cancer Cell International, 12, p.5. doi:10.1186/1475-2867-12-5
21. Yeoh, K.W., Prawira, A., Saad, M.Z.B., Lee, K.M., Lee, E.M.H., Low, G.K., Mohd Nasir, M.H., Phua, J.H., Chia, W.W.L., Lim, I.J.H. & Ong, Y.B., 2020. Vinorelbine augments radiotherapy in hepatocellular carcinoma. Cancers, 12(4), p.872. doi:10.3390/cancers12040872
22. Li, X., Zhang, Y., Liu, L., Wang, J., & Wang, Y. (2014) 'Combination therapy of sorafenib and TACE for unresectable HCC: A systematic review and meta-analysis', PLOS ONE, 9(3), e91124. doi: 10.1371/journal.pone.0091124.
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC9763643/
24. Sun, S., Shen, B., & Wang, N. (2023) 'Concurrent chemoradiotherapy improves prognosis and quality of life of patients with metastatic and recurrent hepatocellular carcinoma', American Journal of Translational Research, 15(1), pp. 233–240.
25. Niu, M., Yi, M., Li, N., Wu, K. & Wu, K. (2021) 'Advances of targeted therapy for hepatocellular carcinoma', Frontiers in Oncology, 11, 719896.
26. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338. doi: 10.1055/s-2007-1007122.
27. Kinoshita, A., Onoda, H., Fushiya, N., Koike, K., Nishino, H. and Tajiri, H. (2015) ‘Staging systems for hepatocellular carcinoma: Current status and future perspectives’, World Journal of Hepatology, 7(3), pp. 406–424. doi: 10.4254/wjh.v7.i3.406.
28. Reig, M., Forner, A., Rimola, J., Ferrer Fàbrega, J., Burrel, M., Garcia Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C. and Bruix, J. (2022) ‘BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update’, Journal of Hepatology, 76(3), pp. 681–693. doi: 10.1016/j.jhep.2021.11.018.
29. Zhong, J.-H. (2024) ‘Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era’, World Journal of Gastroenterology, 30(8), pp. 806–810. doi: 10.3748/wjg.v30.i8.806.
30. Cardarelli-Leite, L., Hadjivassiliou, A., Klass, D., Chung, J., Ho, S.G.F., Lim, H.J., Kim, P.T.W., Mujoomdar, A. and Liu, D.M. (2020) ‘Current locoregional therapies and treatment strategies in hepatocellular carcinoma’, Current Oncology, 27(Suppl. 3), pp. S144–S151. doi:10.3747/ co.27.7171.
31. Rizzo, A., Ricci, A. D. and Brandi, G. (2022) ‘Trans Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update’, Journal of Personalized Medicine, 12(11), p. 1788. doi:10.3390/jpm12111788.
32. Facciorusso, A. (2018) ‘Drug eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art’, World Journal of Gastroenterology, 24(2), pp. 161–169. doi: 10.3748/wjg.v24.i2.161.
33. Keating, G. M. (2017) ‘Sorafenib: A review in hepatocellular carcinoma’, Target Oncology, 12(2), pp. 243–253. doi:10.1007/s11523-017-0484-7.
34. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004;64:7099–7109. doi: 10.1158/0008-5472.CAN-04-1443.
35. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J., Factor V.M., Thorgeirsson S.S. Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC. Gastroenterology. 2006;130:1117–1128. doi: 10.1053/j.gastro.2006.01.006.
36. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., De Greve J., Douillard J.-Y., Lathia C., Schwartz B., et al. Phase II Study of Sorafenib in Patients with Advanced Hepatocellular Carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2006;24:4293–4300. doi: 10.1200/JCO.2005.01.3441.
37. Yeo W., Mok T.S., Zee B., Leung T.W.T., Lai P.B.S., Lau W.Y., Koh J., Mo F.K.F., Yu S.C.H., Chan A.T., et al. A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma. JNCI J. Natl. Cancer Inst. 2005;97:1532–1538. doi: 10.1093/jnci/dji315.
38. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.-F., de Oliveira A.C., Santoro A., Raoul J.-L., Forner A., et al. Sorafenib in Advanced Hepatocellular Carcinoma. N. Engl. J. Med. 2008;359:378–390. doi: 10.1056/NEJMoa0708857.
39. Bruix J., Cheng A.-L., Meinhardt G., Nakajima K., De Sanctis Y., Llovet J. Prognostic Factors and Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma: Analysis of Two Phase III Studies. J. Hepatol. 2017;67:999–1008. doi: 10.1016/j.jhep.2017.06.026.
40. Bruix J., Raoul J.-L., Sherman M., Mazzaferro V., Bolondi L., Craxi A., Galle P.R., Santoro A., Beaugrand M., Sangiovanni A., et al. Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. J. Hepatol. 2012;57:821–829. doi: 10.1016/j.jhep.2012.06.014.
41. Cheng A.-L., Guan Z., Chen Z., Tsao C.-J., Qin S., Kim J.S., Yang T.-S., Tak W.Y., Pan H., Yu S., et al. Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma According to Baseline Status: Subset Analyses of the Phase III Sorafenib Asia–Pacific Trial. Eur. J. Cancer. 2012;48:1452–1465. doi: 10.1016/j.ejca.2011.12.006.
42. Al Salama, Z.T., Syed, Y.Y. and Scott, L.J. (2019) ‘Lenvatinib: A Review in Hepatocellular Carcinoma’, Drugs, 79(6), pp. 635–642. doi: 10.1007/s40265 019 01116 x.
43. Singh, A., Zahid, S., Noginskiy, I., Pak, T., Usta, S., Barsoum, M. and Khan, U. (2022) ‘A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma’, Current Oncology, 29(9), pp. 6445–6462. doi: 10.3390/curroncol29090507.
44. Kudo M., Finn R.S., Qin S., Han K.-H., Ikeda K., Piscaglia F., Baron A., Park J.-W., Han G., Jassem J., et al. Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. Lancet. 2018;391:1163–1173. doi: 10.1016/S0140-6736(18)30207-1.
45. Huynh J., Cho M.T., Kim E.J.-H., Ren M., Robbins C., Amaya-Chanaga C., Vogel A. Post Hoc Analysis in Patients (Pts) with Unresectable Hepatocellular Carcinoma (UHCC) Who Progressed to Child-Pugh B (CPB) Liver Function in the Phase III REFLECT Study of Lenvatinib (LEN) J. Clin. Oncol. 2021;39((Suppl. 3)):298. doi: 10.1200/JCO.2021.39.3_suppl.298.
46. Alsina A., Kudo M., Vogel A., Cheng A.-L., Tak W.Y., Ryoo B.-Y., Evans T.R.J., López López C., Daniele B., Misir S., et al. Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2020;9:93–104. doi: 10.1159/00050 4624.
47. Alsina A., Kudo M., Vogel A., Cheng A.-L., Tak W.Y., Ryoo B.-Y., Evans T.R.J., Lopéz Lopéz C., Daniele B., Blanc J.-F., et al. Subsequent Anticancer Procedures Following First-Line Lenvatinib (LEN): A Post Hoc Analysis from the Phase III REFLECT Study in Unresectable Hepatocellular Carcinoma (UHCC) J. Clin. Oncol. 2020;38((Suppl. 4)):520. doi: 10.1200/JCO.2020.38.4_suppl.520.
48. Liu, X., Lu, Y. and Qin, S. (2021) ‘Atezolizumab and Bevacizumab for Hepatocellular Carcinoma: Mechanism, Pharmacokinetics and Future Treatment Strategies’, Future Oncology, 17(17), pp. 2243–2256. doi: 10.2217/fon 2020 1290.
49. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and Its Ligands in Tolerance and Immunity. Annu. Rev. Immunol. 2008;26:677–704. doi: 10.1146/annurev.immunol.26.02 1607.090331.
50. Gao Q., Wang X.-Y., Qiu S.-J., Yamato I., Sho M., Nakajima Y., Zhou J., Li B.-Z., Shi Y.-H., Xiao Y.-S., et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. Clin. Cancer Res. 2009;15:971–979. doi: 10.1158/1078-0432.CCR-08-1608.
51. Herbst R.S., Soria J.-C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature. 2014;515:563–567. doi: 10.1038/nature14011.
52. Finn R.S., Bentley G., Britten C.D., Amado R., Busuttil R.W. Targeting Vascular Endothelial Growth Factor with the Monoclonal Antibody Bevacizumab Inhibits Human Hepatocellular Carcinoma Cells Growing in an Orthotopic Mouse Model. Liver Int. Off. J. Int. Assoc. Study Liver. 2009;29:284–290. doi: 10.1111/j.1478-3231.2008.01762.x.
53. Lee M.S., Ryoo B.-Y., Hsu C.-H., Numata K., Stein S., Verret W., Hack S.P., Spahn J., Liu B., Abdullah H., et al. GO30140 investigators. Atezolizumab with or without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-Label, Multicentre, Phase 1b Study. Lancet Oncol. 2020;21:808–820. doi: 10.1016/S1470-2045(20)30156-X.
54. Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.-Y., Kudo M., Breder V., Merle P., Kaseb A.O., et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020;382:1894–1905. doi: 10.1056/NEJMoa1915745.
55. Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.-Y., Lim H.Y., Kudo M., Breder V.V., Merle P., et al. IMbrave150: Updated Overall Survival (OS) Data from a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) versus Sorafenib (Sor) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC) J. Clin. Oncol. 2021;39((Suppl. 3)):267. doi: 10.1200/JCO.2021.39.3_suppl.267.
56. Heo, Y.-A. & Syed, Y.Y., 2018. Regorafenib: A Review in Hepatocellular Carcinoma. Drugs, 78(9), pp.951–958. doi:10.1007/s40265-018-0932-4.
57. Frenette C.T. The Role of Regorafenib in Hepatocellular Carcinoma. Gastroenterol. Hepatol. 2017;13:122–124.
58. Bruix J., Qin S., Merle P., Granito A., Huang Y.-H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Breder V., et al. Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Lond. Engl. 2017;389:56–66. doi: 10.1016/S0140-6736(16)32453-9.
59. Finn R.S., Merle P., Granito A., Huang Y.-H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Gerolami R., Caparello C., et al. Outcomes of Sequential Treatment with Sorafenib Followed by Regorafenib for HCC: Additional Analyses from the Phase III RESORCE Trial. J. Hepatol. 2018;69:353–358. doi: 10.1016/j.jhep.2018.04.010.
60. Deeks, E.D., 2019. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma. Targeted Oncology, 14, pp. 107–113.
61. Yakes F.M., Chen J., Tan J., Yamaguchi K., Shi Y., Yu P., Qian F., Chu F., Bentzien F., Cancilla B., et al. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth. Mol. Cancer Ther. 2011;10:2298–2308. doi: 10.1158/1535-7163.MCT-11-0264.
62. Abou-Alfa G.K., Meyer T., Cheng A.-L., El-Khoueiry A.B., Rimassa L., Ryoo B.-Y., Cicin I., Merle P., Chen Y., Park J.-W., et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N. Engl. J. Med. 2018;379:54–63. doi: 10.1056/NEJMoa1717002.
63. Kelley R.K., Meyer T., Rimassa L., Merle P., Park J.-W., Yau T., Chan S.L., Blanc J.-F., Tam V.C., Tran A., et al. Serum Alpha-Fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin. Cancer Res. 2020;26:4795–4804. doi: 10.1158/1078-0432.CCR-19-3884.
64. Syed, Y.Y., 2020. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs, 80(3), pp.315–322. doi:10.1007/s40265 020 01263 6
65. Zhu A.X., Kang Y.-K., Yen C.-J., Finn R.S., Galle P.R., Llovet J.M., Assenat E., Brandi G., Pracht M., Lim H.Y., et al. Ramucirumab after Sorafenib in Patients with Advanced Hepatocellular Carcinoma and Increased α-Fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2019;20:282–296. doi: 10.1016/S1470-2045(18)30937-9.
66. Zhu A.X., Park J.O., Ryoo B.-Y., Yen C.-J., Poon R., Pastorelli D., Blanc J.-F., Chung H.C., Baron A.D., Pfiffer T.E.F., et al. Ramucirumab versus Placebo as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. Lancet Oncol. 2015;16:859–870. doi: 10.1016/S1470-2045(15)00050-9.
67. Choucair K., Kamran S., Saeed A. Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. OncoTargets Ther. 2021;14:5521–5532. doi: 10.2147/OTT.S268309.
68. Chen, Y.H., Wang, C.C., Chen, Y.Y., Houng Wang, J., Hung Chao H., and Kuo, Y.H., 2022. Low dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 22, p. 1153. doi:10.1186/s12885 022 10271 6.
69. El-Khoueiry A.B., Sangro B., Yau T., Crocenzi T.S., Kudo M., Hsu C., Kim T.-Y., Choo S.-P., Trojan J., Welling T.H., et al. Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. Lancet Lond. Engl. 2017;389:2492–2502. doi: 10.1016/S0140-6736(17)31046-2.
70. Yau T., Park J.-W., Finn R.S., Cheng A.-L., Mathurin P., Edeline J., Kudo M., Harding J.J., Merle P., Rosmorduc O., et al. Nivolumab versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. Lancet Oncol. 2022;23:77–90. doi: 10.1016/S1470-2045(21)00604-5.
71. Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D.H., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al., 2018. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. The Lancet Oncology, 19(7), pp.940–952. doi:10.1016/S1470-2045(18)30351-6.
72. Zhu A.X., Finn R.S., Edeline J., Cattan S., Ogasawara S., Palmer D., Verslype C., Zagonel V., Fartoux L., Vogel A., et al. Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. Lancet Oncol. 2018;19:940–952. doi: 10.1016/S1470-2045(18)30351-6.
73. Finn R.S., Ryoo B.-Y., Merle P., Kudo M., Bouattour M., Lim H.Y., Breder V., Edeline J., Chao Y., Ogasawara S., et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020;38:193–202. doi: 10.1200/JCO.19.01307.
74. Wright, M., Woodland, H. & Hudson, B., 2022. Symptom control in advanced chronic liver disease: integrating anticipatory palliative and supportive care. Frontline Gastroenterology, 13, pp.e109–e115. doi:10.1136/flgastro 2022 102114.
75. Kumar, M. and Panda, D. (2014) Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma, Journal of Clinical and Experimental Hepatology, 4(Suppl 3), pp. S130–S139. doi:10.1016/j.jceh.2014.03.049. (Accessed: 27 August 2025).
76. Kumar R., Saraswat M.K., Sharma B.C., Sakhuja P., Sarin S.K. Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM. 2008 Jun;101:479–485. doi: 10.1093/qjmed/hcn033.
77. Lin M.H., Wu P.Y., Tsai S.T., Lin C.L., Chen T.W., Hwang S.J. Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliat Med. 2004;18:93–99. doi: 10.1191/0269216304pm851oa.
78. Zabora J., BrintzenhofeSzoc K., Curbow B., Hooker C., Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10:19–28. doi: 10.1002/1099-1611(200101/02)10:1<19::aid-pon501>3.0.co;2-6.
79. Kim H.J., McGuire D.B., Tulman L., Barsevick A.M. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28:270–282. doi: 10.1097/00002820-200507000-00005.
80. Ryu E., Kim K., Cho M.S., Kwon I.G., Kim H.S., Fu M.R. Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs. 2010;33(1):3–10. doi: 10.1097/NCC.0b013e3181b4367e.
81. Miaskowski C., Dodd M., Lee K. Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monographs. 2004;32:17–21. doi: 10.1093/jncimonographs/lgh023.
82. Morse, M.A.; Sun, W.; Kim, R.; He, A.R.; Abada, P.B.; Mynderse, M.; Finn, R.S. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin. Cancer Res. 2019, 25, 912–920.
83. Zhu, A.X.; Duda, D.G.; Sahani, D.V.; Jain, R.K. HCC and Angiogenesis: Possible Targets and Future Directions. Nat. Rev. Clin. Oncol. 2011, 8, 292–301.
84. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.-F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.-L.; Forner, A.; et al. Sorafenib in Advanced Hepatocellular Carcinoma. N. Engl. J. Med. 2008, 359, 378–390.
85. Cheng, A.-L.; Kang, Y.-K.; Chen, Z.; Tsao, C.-J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.-S.; et al. Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Oncol. 2009, 10, 25–34.
86. Abou-Alfa, G.K.; Johnson, P.; Knox, J.J.; Capanu, M.; Davidenko, I.; Lacava, J.; Leung, T.; Gansukh, B.; Saltz, L.B. Doxorubicin plus Sorafenib vs. Doxorubicin Alone in Patients with Advanced Hepatocellular Carcinoma: A Randomized Trial–PubMed.
87. Cheng, A.-L.; Kang, Y.-K.; Lin, D.-Y.; Park, J.-W.; Kudo, M.; Qin, S.; Chung, H.-C.; Song, X.; Xu, J.; Poggi, G.; et al. Sunitinib versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial. J. Clin. Oncol. 2013, 31, 4067–4075
88. Cainap, C.; Qin, S.; Huang, W.-T.; Chung, I.J.; Pan, H.; Cheng, Y.; Kudo, M.; Kang, Y.-K.; Chen, P.-J.; Toh, H.-C.; et al. Linifanib versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. J. Clin. Oncol. 2015, 33, 172–179.
89. Llovet, J.M.; Decaens, T.; Raoul, J.-L.; Boucher, E.; Kudo, M.; Chang, C.; Kang, Y.-K.; Assenat, E.; Lim, H.-Y.; Boige, V.; et al. Brivanib in Patients with Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results from the Randomized Phase III BRISK-PS Study. J. Clin. Oncol. 2013, 31, 3509–3516.
90. Abou-Alfa, G.K.; Qin, S.; Ryoo, B.-Y.; Lu, S.-N.; Yen, C.-J.; Feng, Y.-H.; Lim, H.Y.; Izzo, F.; Colombo, M.; Sarker, D.; et al. Phase III Randomized Study of Second Line ADI-PEG 20 plus Best Supportive Care versus Placebo plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma. Ann. Oncol. 2018, 29, 1402–1408.
91. Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.-H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; et al. Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 2017, 389, 56–66.
92. Bruix, J.; Merle, P.; Granito, A.; Huang, Y.-H.; Bodoky, G.; Yokosuka, O.; Rosmorduc, O.; Breder, V.V.; Gerolami, R.; Masi, G.; et al. Hand-Foot Skin Reaction (HFSR) and Overall Survival (OS) in the Phase 3 RESORCE Trial of Regorafenib for Treatment of Hepatocellular Carcinoma (HCC) Progressing on Sorafenib. J. Clin. Oncol. 2018, 36, 412.
93. Yamashita, T.; Kudo, M.; Ikeda, K.; Izumi, N.; Tateishi, R.; Ikeda, M.; Aikata, H.; Kawaguchi, Y.; Wada, Y.; Numata, K.; et al. REFLECT-a Phase 3 Trial Comparing Efficacy and Safety of Lenvatinib to Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: An Analysis of Japanese Subset. J. Gastroenterol. 2020, 55, 113–122.
94. Blanc, J.F. Traitement du Carcinome Hépatocellulaire Avancé. Available online: https://www.fmcgastro.org/texte-postu/postu-2019-paris/traitement-du-chc-avance/ (accessed on 28 March 2022).
95. Abou-Alfa, G.K.; Meyer, T.; Cheng, A.-L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.-Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.-W.; et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N. Engl. J. Med. 2018, 379, 54–63.
96. Voron, T.; Colussi, O.; Marcheteau, E.; Pernot, S.; Nizard, M.; Pointet, A.-L.; Latreche, S.; Bergaya, S.; Benhamouda, N.; Tanchot, C.; et al. VEGF-A Modulates Expression of Inhibitory Checkpoints on CD8+ T Cells in Tumors. J. Exp. Med. 2015, 212, 139–148.
97. Wallin, J.J.; Bendell, J.C.; Funke, R.; Sznol, M.; Korski, K.; Jones, S.; Hernandez, G.; Mier, J.; He, X.; Hodi, F.S.; et al. Atezolizumab in Combination with Bevacizumab Enhances Antigen-Specific T-Cell Migration in Metastatic Renal Cell Carcinoma. Nat. Commun. 2016, 7, 12624.
98. Sangro, B.; Sarobe, P.; Hervás-Stubbs, S.; Melero, I. Advances in Immunotherapy for Hepatocellular Carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 525–543.
99. El-Khoueiry, A.B.; Sangro, B.; Yau, T.; Crocenzi, T.S.; Kudo, M.; Hsu, C.; Kim, T.-Y.; Choo, S.-P.; Trojan, J.; Welling, T.H.; et al. Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. Lancet 2017, 389, 2492–2502.
100. Yau, T.; Park, J.-W.; Finn, R.S.; Cheng, A.-L.; Mathurin, P.; Edeline, J.; Kudo, M.; Harding, J.J.; Merle, P.; Rosmorduc, O.; et al. Nivolumab versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. Lancet Oncol. 2022, 23, 77–90.
101. Kuo, Y.-H.; Yen, Y.-H.; Chen, Y.-Y.; Kee, K.-M.; Hung, C.-H.; Lu, S.-N.; Hu, T.-H.; Chen, C.-H.; Wang, J.-H. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Front Oncol. 2021, 11, 683341.
102. Zhu, A.X.; Finn, R.S.; Edeline, J.; Cattan, S.; Ogasawara, S.; Palmer, D.; Verslype, C.; Zagonel, V.; Fartoux, L.; Vogel, A.; et al. Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. Lancet Oncol. 2018, 19, 940–952.
103. Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.-Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905.
104. Finn, R.S.; Ikeda, M.; Zhu, A.X.; Sung, M.W.; Baron, A.D.; Kudo, M.; Okusaka, T.; Kobayashi, M.; Kumada, H.; Kaneko, S.; et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. J. Clin. Oncol. 2020, 38, 2960–2970.
105. Kelley, R.K.; Yau, T.; Cheng, A.-L.; Kaseb, A.; Qin, S.; Zhu, A.X.; Chan, S.; Sukeepaisarnjaroen, W.; Breder, V.; Verset, G.; et al. VP10-2021: Cabozantinib (C) plus Atezolizumab (A) versus Sorafenib (S) as First-Line Systemic Treatment for Advanced Hepatocellular Carcinoma (AHCC): Results from the Randomized Phase III COSMIC-312 Trial. Ann. Oncol. 2022, 33, 114–116.
2. Amin, N., Anwar, J., Sulaiman, A., Naumova, N. N. & Anwar, N., 2025. Hepatocellular Carcinoma: A Comprehensive Review. Diseases, 13(7), 207. doi:10.3390/diseases13070207
3. Wu, C.-Y., Lin, L.-Y., Lee, T.-Y., Hsu, Y.-C., Yeh, C.-C., Chen, C., Kang, Y.-N. & Huang, T.-W., 2024. Clinical guidelines for early hepatocellular carcinoma treatment options: a systematic review and bibliometric analysis. International Journal of Surgery, 110(11), pp.7234–7244. doi:10.1097/JS9.0000000000001950.
4. Zheng, S., Chan, S.W., Liu, F., Liu, J., Chow, P.K.H., Toh, H.C. & Hong, W., 2024. Hepatocellular carcinoma: current drug therapeutic status, advances and challenges. Cancers, 16(8), 1582.
5. Hatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S., 2023. Treatment Strategy for Intermediate Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers, 15(6), 1798. DOI: 10.3390/cancers15061798.
6. https://www.sciencedirect.com/science/article/abs/pii/S0305737210001313
7. Rose, M.G., Kennedy, E.B., Abou-Alfa, G.K., Finn, R.S., Gade, T., Kelley, R., Taddei, T., Gordan, J.D., 2024. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. Journal of Clinical Oncology, 42(8), pp. 1–14.
8. Zhou, Y., Zhang, Y., Wang, Z., Wang, J., Li, X., Xu, X., et al., 2025. Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation. Frontiers in Pharmacology, 14, 1581820
9. Chava, S., Ekmen, N., Ferraris, P., Aydin, Y., Moroz, K., Wu, T., Thung, S.N. & Dash, S., 2024. Mechanisms of Sorafenib Resistance in HCC Culture Relate to the Impaired Membrane Expression of Organic Cation Transporter 1 (OCT1). Journal of Hepatocellular Carcinoma, 11, pp. 839–855. doi:10.2147/JHC.S452152
10. Chen, S., Du, Y., Guan, X.-Y. & Yan, Q., 2023. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma. Frontiers in Oncology, 13, 1204513. doi:10.3389/fonc.2023.1204513
11. Suyama, K. & Iwase, H., 2018. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control, 25(1), 1073274818789361. doi:10.1177/1073274818789361
12. Grothey, A., Blay, J.-Y., Pavlakis, N., Yoshino, T. & Bruix, J., 2020. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews, 86, 101993. doi:10.1016/j.ctrv.2020.101993
13. Maroto, P., Porta, C., Capdevila, J., Apolo, A.B., Viteri, S., Rodriguez Antona, C., Martín, L. & Castellano, D., 2022. Cabozantinib for the treatment of solid tumours: a systematic review. Therapeutic Advances in Medical Oncology, 14, 17588359221107112. doi:10.1177/17588359221107112
14. Takebe, N., Beumer, J. H., Kummar, S., et al., 2019. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. British Journal of Clinical Pharmacology, 85(11), pp.2499–2511. doi:10.1111/bcp.14054
15. Jones, R.L., Ratain, M.J., O’Dwyer, P.J., Siu, L.L., Jassem, J., Medioni, J., DeJonge, M., Rudin, C., Sawyer, M., Khayat, D., Awada, A., de Vos Geelen, J.M.P.G.M., Evans, T.R.J., Obel, J., Brockstein, B., DeGreve, J., Baurain, J.-F., Maki, R., D’Adamo, D., Dickson, M., Undevia, S., Geary, D., Janisch, L., Bedard, P.L., Abdul Razak, A.R., Kristeleit, R., Vitfell Rasmussen, J., Walters, I., Kaye, S.B. & Schwartz, G., 2019. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 120, pp.132–139. doi:10.1016/j.ejca.2019.07.024
16. Chaudhari, M., Kumari, N., & Singh, S., 2025. Emerging Research and Future Directions on Doxorubicin: A Snapshot. Asian Pacific Journal of Cancer Prevention, 26(1), pp.5–14. doi:10.31557/APJCP.2025.26.1.5
17. Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S.A., Basiri, A. & Taheri, M., 2021. 5-Fluorouracil: A narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent. Frontiers in Oncology, 11, p.658636. doi:10.3389/fonc.2021.658636
18. Zhang, J., Zong, Y., Xu, G.-Z. & Xing, K., 2016. Erlotinib for advanced hepatocellular carcinoma: A systematic review of phase II/III clinical trials. Saudi Medical Journal, 37(11), pp.1184–1190. doi:10.15537/smj.2016.11.16267
19. Yamanaka, K., Petrulionis, M., Lin, S., Gao, C., Galli, U., Richter, S., Winkler, S., Houben, P., Schultze, D., Hatano, E. & Schemmer, P., 2013. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis. Cancer Medicine, 2(6), pp.862–871. doi:10.1002/cam4.150
20. Hijona, E., Banales, J.M., Hijona, L., Medina, J.F., Arenas, J., Herreros-Villanueva, M., Aldazabal, P. & Bujanda, L., 2012. Pravastatin inhibits cell proliferation and increases MAT1A expression in hepatocarcinoma cells and in vivo models. Cancer Cell International, 12, p.5. doi:10.1186/1475-2867-12-5
21. Yeoh, K.W., Prawira, A., Saad, M.Z.B., Lee, K.M., Lee, E.M.H., Low, G.K., Mohd Nasir, M.H., Phua, J.H., Chia, W.W.L., Lim, I.J.H. & Ong, Y.B., 2020. Vinorelbine augments radiotherapy in hepatocellular carcinoma. Cancers, 12(4), p.872. doi:10.3390/cancers12040872
22. Li, X., Zhang, Y., Liu, L., Wang, J., & Wang, Y. (2014) 'Combination therapy of sorafenib and TACE for unresectable HCC: A systematic review and meta-analysis', PLOS ONE, 9(3), e91124. doi: 10.1371/journal.pone.0091124.
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC9763643/
24. Sun, S., Shen, B., & Wang, N. (2023) 'Concurrent chemoradiotherapy improves prognosis and quality of life of patients with metastatic and recurrent hepatocellular carcinoma', American Journal of Translational Research, 15(1), pp. 233–240.
25. Niu, M., Yi, M., Li, N., Wu, K. & Wu, K. (2021) 'Advances of targeted therapy for hepatocellular carcinoma', Frontiers in Oncology, 11, 719896.
26. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338. doi: 10.1055/s-2007-1007122.
27. Kinoshita, A., Onoda, H., Fushiya, N., Koike, K., Nishino, H. and Tajiri, H. (2015) ‘Staging systems for hepatocellular carcinoma: Current status and future perspectives’, World Journal of Hepatology, 7(3), pp. 406–424. doi: 10.4254/wjh.v7.i3.406.
28. Reig, M., Forner, A., Rimola, J., Ferrer Fàbrega, J., Burrel, M., Garcia Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C. and Bruix, J. (2022) ‘BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update’, Journal of Hepatology, 76(3), pp. 681–693. doi: 10.1016/j.jhep.2021.11.018.
29. Zhong, J.-H. (2024) ‘Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era’, World Journal of Gastroenterology, 30(8), pp. 806–810. doi: 10.3748/wjg.v30.i8.806.
30. Cardarelli-Leite, L., Hadjivassiliou, A., Klass, D., Chung, J., Ho, S.G.F., Lim, H.J., Kim, P.T.W., Mujoomdar, A. and Liu, D.M. (2020) ‘Current locoregional therapies and treatment strategies in hepatocellular carcinoma’, Current Oncology, 27(Suppl. 3), pp. S144–S151. doi:10.3747/ co.27.7171.
31. Rizzo, A., Ricci, A. D. and Brandi, G. (2022) ‘Trans Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update’, Journal of Personalized Medicine, 12(11), p. 1788. doi:10.3390/jpm12111788.
32. Facciorusso, A. (2018) ‘Drug eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art’, World Journal of Gastroenterology, 24(2), pp. 161–169. doi: 10.3748/wjg.v24.i2.161.
33. Keating, G. M. (2017) ‘Sorafenib: A review in hepatocellular carcinoma’, Target Oncology, 12(2), pp. 243–253. doi:10.1007/s11523-017-0484-7.
34. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004;64:7099–7109. doi: 10.1158/0008-5472.CAN-04-1443.
35. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J., Factor V.M., Thorgeirsson S.S. Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC. Gastroenterology. 2006;130:1117–1128. doi: 10.1053/j.gastro.2006.01.006.
36. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., De Greve J., Douillard J.-Y., Lathia C., Schwartz B., et al. Phase II Study of Sorafenib in Patients with Advanced Hepatocellular Carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2006;24:4293–4300. doi: 10.1200/JCO.2005.01.3441.
37. Yeo W., Mok T.S., Zee B., Leung T.W.T., Lai P.B.S., Lau W.Y., Koh J., Mo F.K.F., Yu S.C.H., Chan A.T., et al. A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma. JNCI J. Natl. Cancer Inst. 2005;97:1532–1538. doi: 10.1093/jnci/dji315.
38. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.-F., de Oliveira A.C., Santoro A., Raoul J.-L., Forner A., et al. Sorafenib in Advanced Hepatocellular Carcinoma. N. Engl. J. Med. 2008;359:378–390. doi: 10.1056/NEJMoa0708857.
39. Bruix J., Cheng A.-L., Meinhardt G., Nakajima K., De Sanctis Y., Llovet J. Prognostic Factors and Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma: Analysis of Two Phase III Studies. J. Hepatol. 2017;67:999–1008. doi: 10.1016/j.jhep.2017.06.026.
40. Bruix J., Raoul J.-L., Sherman M., Mazzaferro V., Bolondi L., Craxi A., Galle P.R., Santoro A., Beaugrand M., Sangiovanni A., et al. Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. J. Hepatol. 2012;57:821–829. doi: 10.1016/j.jhep.2012.06.014.
41. Cheng A.-L., Guan Z., Chen Z., Tsao C.-J., Qin S., Kim J.S., Yang T.-S., Tak W.Y., Pan H., Yu S., et al. Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma According to Baseline Status: Subset Analyses of the Phase III Sorafenib Asia–Pacific Trial. Eur. J. Cancer. 2012;48:1452–1465. doi: 10.1016/j.ejca.2011.12.006.
42. Al Salama, Z.T., Syed, Y.Y. and Scott, L.J. (2019) ‘Lenvatinib: A Review in Hepatocellular Carcinoma’, Drugs, 79(6), pp. 635–642. doi: 10.1007/s40265 019 01116 x.
43. Singh, A., Zahid, S., Noginskiy, I., Pak, T., Usta, S., Barsoum, M. and Khan, U. (2022) ‘A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma’, Current Oncology, 29(9), pp. 6445–6462. doi: 10.3390/curroncol29090507.
44. Kudo M., Finn R.S., Qin S., Han K.-H., Ikeda K., Piscaglia F., Baron A., Park J.-W., Han G., Jassem J., et al. Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. Lancet. 2018;391:1163–1173. doi: 10.1016/S0140-6736(18)30207-1.
45. Huynh J., Cho M.T., Kim E.J.-H., Ren M., Robbins C., Amaya-Chanaga C., Vogel A. Post Hoc Analysis in Patients (Pts) with Unresectable Hepatocellular Carcinoma (UHCC) Who Progressed to Child-Pugh B (CPB) Liver Function in the Phase III REFLECT Study of Lenvatinib (LEN) J. Clin. Oncol. 2021;39((Suppl. 3)):298. doi: 10.1200/JCO.2021.39.3_suppl.298.
46. Alsina A., Kudo M., Vogel A., Cheng A.-L., Tak W.Y., Ryoo B.-Y., Evans T.R.J., López López C., Daniele B., Misir S., et al. Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2020;9:93–104. doi: 10.1159/00050 4624.
47. Alsina A., Kudo M., Vogel A., Cheng A.-L., Tak W.Y., Ryoo B.-Y., Evans T.R.J., Lopéz Lopéz C., Daniele B., Blanc J.-F., et al. Subsequent Anticancer Procedures Following First-Line Lenvatinib (LEN): A Post Hoc Analysis from the Phase III REFLECT Study in Unresectable Hepatocellular Carcinoma (UHCC) J. Clin. Oncol. 2020;38((Suppl. 4)):520. doi: 10.1200/JCO.2020.38.4_suppl.520.
48. Liu, X., Lu, Y. and Qin, S. (2021) ‘Atezolizumab and Bevacizumab for Hepatocellular Carcinoma: Mechanism, Pharmacokinetics and Future Treatment Strategies’, Future Oncology, 17(17), pp. 2243–2256. doi: 10.2217/fon 2020 1290.
49. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and Its Ligands in Tolerance and Immunity. Annu. Rev. Immunol. 2008;26:677–704. doi: 10.1146/annurev.immunol.26.02 1607.090331.
50. Gao Q., Wang X.-Y., Qiu S.-J., Yamato I., Sho M., Nakajima Y., Zhou J., Li B.-Z., Shi Y.-H., Xiao Y.-S., et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. Clin. Cancer Res. 2009;15:971–979. doi: 10.1158/1078-0432.CCR-08-1608.
51. Herbst R.S., Soria J.-C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature. 2014;515:563–567. doi: 10.1038/nature14011.
52. Finn R.S., Bentley G., Britten C.D., Amado R., Busuttil R.W. Targeting Vascular Endothelial Growth Factor with the Monoclonal Antibody Bevacizumab Inhibits Human Hepatocellular Carcinoma Cells Growing in an Orthotopic Mouse Model. Liver Int. Off. J. Int. Assoc. Study Liver. 2009;29:284–290. doi: 10.1111/j.1478-3231.2008.01762.x.
53. Lee M.S., Ryoo B.-Y., Hsu C.-H., Numata K., Stein S., Verret W., Hack S.P., Spahn J., Liu B., Abdullah H., et al. GO30140 investigators. Atezolizumab with or without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-Label, Multicentre, Phase 1b Study. Lancet Oncol. 2020;21:808–820. doi: 10.1016/S1470-2045(20)30156-X.
54. Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.-Y., Kudo M., Breder V., Merle P., Kaseb A.O., et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020;382:1894–1905. doi: 10.1056/NEJMoa1915745.
55. Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.-Y., Lim H.Y., Kudo M., Breder V.V., Merle P., et al. IMbrave150: Updated Overall Survival (OS) Data from a Global, Randomized, Open-Label Phase III Study of Atezolizumab (Atezo) + Bevacizumab (Bev) versus Sorafenib (Sor) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC) J. Clin. Oncol. 2021;39((Suppl. 3)):267. doi: 10.1200/JCO.2021.39.3_suppl.267.
56. Heo, Y.-A. & Syed, Y.Y., 2018. Regorafenib: A Review in Hepatocellular Carcinoma. Drugs, 78(9), pp.951–958. doi:10.1007/s40265-018-0932-4.
57. Frenette C.T. The Role of Regorafenib in Hepatocellular Carcinoma. Gastroenterol. Hepatol. 2017;13:122–124.
58. Bruix J., Qin S., Merle P., Granito A., Huang Y.-H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Breder V., et al. Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Lond. Engl. 2017;389:56–66. doi: 10.1016/S0140-6736(16)32453-9.
59. Finn R.S., Merle P., Granito A., Huang Y.-H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Gerolami R., Caparello C., et al. Outcomes of Sequential Treatment with Sorafenib Followed by Regorafenib for HCC: Additional Analyses from the Phase III RESORCE Trial. J. Hepatol. 2018;69:353–358. doi: 10.1016/j.jhep.2018.04.010.
60. Deeks, E.D., 2019. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma. Targeted Oncology, 14, pp. 107–113.
61. Yakes F.M., Chen J., Tan J., Yamaguchi K., Shi Y., Yu P., Qian F., Chu F., Bentzien F., Cancilla B., et al. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth. Mol. Cancer Ther. 2011;10:2298–2308. doi: 10.1158/1535-7163.MCT-11-0264.
62. Abou-Alfa G.K., Meyer T., Cheng A.-L., El-Khoueiry A.B., Rimassa L., Ryoo B.-Y., Cicin I., Merle P., Chen Y., Park J.-W., et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N. Engl. J. Med. 2018;379:54–63. doi: 10.1056/NEJMoa1717002.
63. Kelley R.K., Meyer T., Rimassa L., Merle P., Park J.-W., Yau T., Chan S.L., Blanc J.-F., Tam V.C., Tran A., et al. Serum Alpha-Fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin. Cancer Res. 2020;26:4795–4804. doi: 10.1158/1078-0432.CCR-19-3884.
64. Syed, Y.Y., 2020. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs, 80(3), pp.315–322. doi:10.1007/s40265 020 01263 6
65. Zhu A.X., Kang Y.-K., Yen C.-J., Finn R.S., Galle P.R., Llovet J.M., Assenat E., Brandi G., Pracht M., Lim H.Y., et al. Ramucirumab after Sorafenib in Patients with Advanced Hepatocellular Carcinoma and Increased α-Fetoprotein Concentrations (REACH-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2019;20:282–296. doi: 10.1016/S1470-2045(18)30937-9.
66. Zhu A.X., Park J.O., Ryoo B.-Y., Yen C.-J., Poon R., Pastorelli D., Blanc J.-F., Chung H.C., Baron A.D., Pfiffer T.E.F., et al. Ramucirumab versus Placebo as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. Lancet Oncol. 2015;16:859–870. doi: 10.1016/S1470-2045(15)00050-9.
67. Choucair K., Kamran S., Saeed A. Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. OncoTargets Ther. 2021;14:5521–5532. doi: 10.2147/OTT.S268309.
68. Chen, Y.H., Wang, C.C., Chen, Y.Y., Houng Wang, J., Hung Chao H., and Kuo, Y.H., 2022. Low dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 22, p. 1153. doi:10.1186/s12885 022 10271 6.
69. El-Khoueiry A.B., Sangro B., Yau T., Crocenzi T.S., Kudo M., Hsu C., Kim T.-Y., Choo S.-P., Trojan J., Welling T.H., et al. Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. Lancet Lond. Engl. 2017;389:2492–2502. doi: 10.1016/S0140-6736(17)31046-2.
70. Yau T., Park J.-W., Finn R.S., Cheng A.-L., Mathurin P., Edeline J., Kudo M., Harding J.J., Merle P., Rosmorduc O., et al. Nivolumab versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. Lancet Oncol. 2022;23:77–90. doi: 10.1016/S1470-2045(21)00604-5.
71. Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D.H., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al., 2018. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. The Lancet Oncology, 19(7), pp.940–952. doi:10.1016/S1470-2045(18)30351-6.
72. Zhu A.X., Finn R.S., Edeline J., Cattan S., Ogasawara S., Palmer D., Verslype C., Zagonel V., Fartoux L., Vogel A., et al. Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. Lancet Oncol. 2018;19:940–952. doi: 10.1016/S1470-2045(18)30351-6.
73. Finn R.S., Ryoo B.-Y., Merle P., Kudo M., Bouattour M., Lim H.Y., Breder V., Edeline J., Chao Y., Ogasawara S., et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020;38:193–202. doi: 10.1200/JCO.19.01307.
74. Wright, M., Woodland, H. & Hudson, B., 2022. Symptom control in advanced chronic liver disease: integrating anticipatory palliative and supportive care. Frontline Gastroenterology, 13, pp.e109–e115. doi:10.1136/flgastro 2022 102114.
75. Kumar, M. and Panda, D. (2014) Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma, Journal of Clinical and Experimental Hepatology, 4(Suppl 3), pp. S130–S139. doi:10.1016/j.jceh.2014.03.049. (Accessed: 27 August 2025).
76. Kumar R., Saraswat M.K., Sharma B.C., Sakhuja P., Sarin S.K. Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM. 2008 Jun;101:479–485. doi: 10.1093/qjmed/hcn033.
77. Lin M.H., Wu P.Y., Tsai S.T., Lin C.L., Chen T.W., Hwang S.J. Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliat Med. 2004;18:93–99. doi: 10.1191/0269216304pm851oa.
78. Zabora J., BrintzenhofeSzoc K., Curbow B., Hooker C., Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10:19–28. doi: 10.1002/1099-1611(200101/02)10:1<19::aid-pon501>3.0.co;2-6.
79. Kim H.J., McGuire D.B., Tulman L., Barsevick A.M. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28:270–282. doi: 10.1097/00002820-200507000-00005.
80. Ryu E., Kim K., Cho M.S., Kwon I.G., Kim H.S., Fu M.R. Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. Cancer Nurs. 2010;33(1):3–10. doi: 10.1097/NCC.0b013e3181b4367e.
81. Miaskowski C., Dodd M., Lee K. Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monographs. 2004;32:17–21. doi: 10.1093/jncimonographs/lgh023.
82. Morse, M.A.; Sun, W.; Kim, R.; He, A.R.; Abada, P.B.; Mynderse, M.; Finn, R.S. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin. Cancer Res. 2019, 25, 912–920.
83. Zhu, A.X.; Duda, D.G.; Sahani, D.V.; Jain, R.K. HCC and Angiogenesis: Possible Targets and Future Directions. Nat. Rev. Clin. Oncol. 2011, 8, 292–301.
84. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.-F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.-L.; Forner, A.; et al. Sorafenib in Advanced Hepatocellular Carcinoma. N. Engl. J. Med. 2008, 359, 378–390.
85. Cheng, A.-L.; Kang, Y.-K.; Chen, Z.; Tsao, C.-J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.-S.; et al. Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Oncol. 2009, 10, 25–34.
86. Abou-Alfa, G.K.; Johnson, P.; Knox, J.J.; Capanu, M.; Davidenko, I.; Lacava, J.; Leung, T.; Gansukh, B.; Saltz, L.B. Doxorubicin plus Sorafenib vs. Doxorubicin Alone in Patients with Advanced Hepatocellular Carcinoma: A Randomized Trial–PubMed.
87. Cheng, A.-L.; Kang, Y.-K.; Lin, D.-Y.; Park, J.-W.; Kudo, M.; Qin, S.; Chung, H.-C.; Song, X.; Xu, J.; Poggi, G.; et al. Sunitinib versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial. J. Clin. Oncol. 2013, 31, 4067–4075
88. Cainap, C.; Qin, S.; Huang, W.-T.; Chung, I.J.; Pan, H.; Cheng, Y.; Kudo, M.; Kang, Y.-K.; Chen, P.-J.; Toh, H.-C.; et al. Linifanib versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. J. Clin. Oncol. 2015, 33, 172–179.
89. Llovet, J.M.; Decaens, T.; Raoul, J.-L.; Boucher, E.; Kudo, M.; Chang, C.; Kang, Y.-K.; Assenat, E.; Lim, H.-Y.; Boige, V.; et al. Brivanib in Patients with Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results from the Randomized Phase III BRISK-PS Study. J. Clin. Oncol. 2013, 31, 3509–3516.
90. Abou-Alfa, G.K.; Qin, S.; Ryoo, B.-Y.; Lu, S.-N.; Yen, C.-J.; Feng, Y.-H.; Lim, H.Y.; Izzo, F.; Colombo, M.; Sarker, D.; et al. Phase III Randomized Study of Second Line ADI-PEG 20 plus Best Supportive Care versus Placebo plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma. Ann. Oncol. 2018, 29, 1402–1408.
91. Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.-H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; et al. Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 2017, 389, 56–66.
92. Bruix, J.; Merle, P.; Granito, A.; Huang, Y.-H.; Bodoky, G.; Yokosuka, O.; Rosmorduc, O.; Breder, V.V.; Gerolami, R.; Masi, G.; et al. Hand-Foot Skin Reaction (HFSR) and Overall Survival (OS) in the Phase 3 RESORCE Trial of Regorafenib for Treatment of Hepatocellular Carcinoma (HCC) Progressing on Sorafenib. J. Clin. Oncol. 2018, 36, 412.
93. Yamashita, T.; Kudo, M.; Ikeda, K.; Izumi, N.; Tateishi, R.; Ikeda, M.; Aikata, H.; Kawaguchi, Y.; Wada, Y.; Numata, K.; et al. REFLECT-a Phase 3 Trial Comparing Efficacy and Safety of Lenvatinib to Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: An Analysis of Japanese Subset. J. Gastroenterol. 2020, 55, 113–122.
94. Blanc, J.F. Traitement du Carcinome Hépatocellulaire Avancé. Available online: https://www.fmcgastro.org/texte-postu/postu-2019-paris/traitement-du-chc-avance/ (accessed on 28 March 2022).
95. Abou-Alfa, G.K.; Meyer, T.; Cheng, A.-L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.-Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.-W.; et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N. Engl. J. Med. 2018, 379, 54–63.
96. Voron, T.; Colussi, O.; Marcheteau, E.; Pernot, S.; Nizard, M.; Pointet, A.-L.; Latreche, S.; Bergaya, S.; Benhamouda, N.; Tanchot, C.; et al. VEGF-A Modulates Expression of Inhibitory Checkpoints on CD8+ T Cells in Tumors. J. Exp. Med. 2015, 212, 139–148.
97. Wallin, J.J.; Bendell, J.C.; Funke, R.; Sznol, M.; Korski, K.; Jones, S.; Hernandez, G.; Mier, J.; He, X.; Hodi, F.S.; et al. Atezolizumab in Combination with Bevacizumab Enhances Antigen-Specific T-Cell Migration in Metastatic Renal Cell Carcinoma. Nat. Commun. 2016, 7, 12624.
98. Sangro, B.; Sarobe, P.; Hervás-Stubbs, S.; Melero, I. Advances in Immunotherapy for Hepatocellular Carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 525–543.
99. El-Khoueiry, A.B.; Sangro, B.; Yau, T.; Crocenzi, T.S.; Kudo, M.; Hsu, C.; Kim, T.-Y.; Choo, S.-P.; Trojan, J.; Welling, T.H.; et al. Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. Lancet 2017, 389, 2492–2502.
100. Yau, T.; Park, J.-W.; Finn, R.S.; Cheng, A.-L.; Mathurin, P.; Edeline, J.; Kudo, M.; Harding, J.J.; Merle, P.; Rosmorduc, O.; et al. Nivolumab versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial. Lancet Oncol. 2022, 23, 77–90.
101. Kuo, Y.-H.; Yen, Y.-H.; Chen, Y.-Y.; Kee, K.-M.; Hung, C.-H.; Lu, S.-N.; Hu, T.-H.; Chen, C.-H.; Wang, J.-H. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Front Oncol. 2021, 11, 683341.
102. Zhu, A.X.; Finn, R.S.; Edeline, J.; Cattan, S.; Ogasawara, S.; Palmer, D.; Verslype, C.; Zagonel, V.; Fartoux, L.; Vogel, A.; et al. Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. Lancet Oncol. 2018, 19, 940–952.
103. Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.-Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905.
104. Finn, R.S.; Ikeda, M.; Zhu, A.X.; Sung, M.W.; Baron, A.D.; Kudo, M.; Okusaka, T.; Kobayashi, M.; Kumada, H.; Kaneko, S.; et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. J. Clin. Oncol. 2020, 38, 2960–2970.
105. Kelley, R.K.; Yau, T.; Cheng, A.-L.; Kaseb, A.; Qin, S.; Zhu, A.X.; Chan, S.; Sukeepaisarnjaroen, W.; Breder, V.; Verset, G.; et al. VP10-2021: Cabozantinib (C) plus Atezolizumab (A) versus Sorafenib (S) as First-Line Systemic Treatment for Advanced Hepatocellular Carcinoma (AHCC): Results from the Randomized Phase III COSMIC-312 Trial. Ann. Oncol. 2022, 33, 114–116.
Article Sidebar
Published
Oct 14, 2025
Article Details
How to Cite
Sahil Prajapati, Dr. Shweta Paroha, & Dr. Pragnesh Patani. (2025). STAGE-SPECIFIC DRUG THERAPIES AND TREATMENT STRATEGIES FOR HEPATOCELLULAR CARCINOMA. Journal of Population Therapeutics and Clinical Pharmacology, 32(7), 1986-2004. https://doi.org/10.53555/3w8p3363
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Sahil Prajapati
Khyati College of Pharmacy, Palodia, Ahmedabad
Dr. Shweta Paroha
Khyati College of Pharmacy, Palodia, Ahmedabad
Dr. Pragnesh Patani
Khyati College of Pharmacy, Palodia, Ahmedabad
How to Cite
Sahil Prajapati, Dr. Shweta Paroha, & Dr. Pragnesh Patani. (2025). STAGE-SPECIFIC DRUG THERAPIES AND TREATMENT STRATEGIES FOR HEPATOCELLULAR CARCINOMA. Journal of Population Therapeutics and Clinical Pharmacology, 32(7), 1986-2004. https://doi.org/10.53555/3w8p3363